– Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; New Collaboration to Advance the Development of Two of Taysha’s Novel Product Candidates for Rare Monogenic Central Nervous System Disorders with Serious Unmet Medical Needs –
– Astellas to invest a total of US$50 million to acquire 15% of the company and receive an exclusive option to acquire an exclusive license to TSHA-102 for Rett Syndrome and TSHA-120 for Giant Axonal Neuropathy (GAN) –
– Astellas Receives Certain Rights in Relation to a Potential Change of Control at Taysha –
– Astellas gains observer seat on Taysha board –

TOKYO and DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Taysha Gene Therapies, Inc. TSHARA “Taysha”))) today announced a strategic investment to support the advancement of Taysha’s adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett Syndrome and GAN. Future options to potentially apply Astellas’ global gene therapy R&D, manufacturing and commercialization capabilities to Taysha’s innovative AAV gene therapy development programs for genetic disorders of the central nervous system (CNS) create an opportunity for the two companies to pursue the development of novel products to improve treatment options for patients with Rett Syndrome and GAN who have serious unmet medical needs.

Under the terms of the agreement, Astellas will invest a total of $50 million to acquire 15% of Taysha’s outstanding common stock and receive an exclusive option to license two of Taysha’s clinical-stage programs: TSHA-102 for Rett Syndrome and TSHA-120 for GAN. In addition, Taysha has granted Astellas certain rights in connection with a possible change of control at Taysha. Definitive agreements would be entered into upon the exercise of such option by Astellas and any change of control transaction would require Tayshas approval.